Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing.
The post Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug appeared first on MedCity News.
